Abstract
Induced pluripotent stem cells have displayed great potential in disease investigation and drug development applications. However, selection of reprogramming factors in each cell type or disease state is both expensive and time consuming. To deal with this kind of situation, a fast computational framework was developed by optimize the reprogramming factors via the protein interaction network and gene functional profiles. It can be used to select reprogramming factors from millions of possibilities. It is anticipated that the novel approach will become a very useful tool for both basic research and drug development.
Keywords: Stem cells, Reprogramming factors, Protein interaction network, Gene functional profiles, Disease investigation, pluripotent stem cells, cDNA sequences, Yamanaka factors, Candidate pluripotency genes, STRING network, Dijkstra, ’, s algorithm, HGF-induced hepatomegaly, ESCs, c-Myc, Gene Ontology
Protein & Peptide Letters
Title: Selection of Reprogramming Factors of Induced Pluripotent Stem Cells Based on the Protein Interaction Network and Functional Profiles
Volume: 19 Issue: 1
Author(s): Tao Huang, Yu-Dong Cai, Lei Chen, Le-Le Hu, Xiang-Yin Kong, Yi-Xue Li and Kuo-Chen Chou
Affiliation:
Keywords: Stem cells, Reprogramming factors, Protein interaction network, Gene functional profiles, Disease investigation, pluripotent stem cells, cDNA sequences, Yamanaka factors, Candidate pluripotency genes, STRING network, Dijkstra, ’, s algorithm, HGF-induced hepatomegaly, ESCs, c-Myc, Gene Ontology
Abstract: Induced pluripotent stem cells have displayed great potential in disease investigation and drug development applications. However, selection of reprogramming factors in each cell type or disease state is both expensive and time consuming. To deal with this kind of situation, a fast computational framework was developed by optimize the reprogramming factors via the protein interaction network and gene functional profiles. It can be used to select reprogramming factors from millions of possibilities. It is anticipated that the novel approach will become a very useful tool for both basic research and drug development.
Export Options
About this article
Cite this article as:
Huang Tao, Cai Yu-Dong, Chen Lei, Hu Le-Le, Kong Xiang-Yin, Li Yi-Xue and Chou Kuo-Chen, Selection of Reprogramming Factors of Induced Pluripotent Stem Cells Based on the Protein Interaction Network and Functional Profiles, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472884
DOI https://dx.doi.org/10.2174/092986612798472884 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions
Current Cancer Drug Targets Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Apoptosis in Physiological and Pathological Skin: Implications for Therapy
Current Molecular Medicine Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Application of Nano- and Micro-Particles on the Topical Therapy of Skin-Related Immune Disorders
Current Pharmaceutical Design Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets Diterpenoids- Potential Chemopreventive and Chemotherapeutic Agents in Leukemia
Current Pharmaceutical Biotechnology Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Hematological Targets of Radiation Damage
Current Drug Targets